|
1
|
Crocetti E, Trama A, Stiller C, Caldarella
A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J and
Brandes A; RARECARE working group, : Epidemiology of glial and
non-glial brain tumours in Europe. Eur J Cancer. 48:1532–1542.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davis FG, Smith TR, Gittleman HR, Ostrom
QT, Kruchko C and Barnholtz-Sloan JS: Glioblastoma incidence rate
trends in Canada and the United States compared with England,
1995–2015. Neuro Oncol. 22:301–302. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Philips A, Henshaw DL, Lamburn G and
O'Carroll MJ: Brain tumours: Rise in glioblastoma multiforme
incidence in England 1995–2015 suggests an adverse environmental or
lifestyle factor. J Environ Public Health. 2018:79107542018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JH, Lee JE, Kahng JY, Kim SH, Park JS,
Yoon SJ, Um JY, Kim WK, Lee JK, Park J, et al: Human glioblastoma
arises from subventricular zone cells with low-level driver
mutations. Nature. 560:243–247. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lah TT, Novak M and Breznik B: Brain
malignancies: Glioblastoma and brain metastases. Semin Cancer Biol.
60:262–273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sturm D, Witt H, Hovestadt V, Khuong-Quang
DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, et
al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic
and biological subgroups of glioblastoma. Cancer Cell. 22:425–437.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Hu B, Hu X, Kim H, Squatrito M,
Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor
evolution of glioma-intrinsic gene expression subtypes associates
with immunological changes in the microenvironment. Cancer Cell.
32:42–56.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Daniel M, Peek GW and Tollefsbol TO:
Regulation of the human catalytic subunit of telomerase (hTERT).
Gene. 498:135–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gilbert MR, Wang M, Aldape KD, Stupp R,
Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT,
et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A
randomized phase III clinical trial. J Clin Oncol. 31:4085–4091.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: a randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fountain DM, Bryant A, Barone DG, Waqar M,
Hart MG, Bulbeck H, Kernohan A, Watts C and Jenkinson MD:
Intraoperative imaging technology to maximise extent of resection
for glioma: A network meta-analysis. Cochrane Database Syst Rev.
1:CD0136302021.PubMed/NCBI
|
|
14
|
Cahill DP, Levine KK, Betensky RA, Codd
PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR,
Curry WT, et al: Loss of the mismatch repair protein MSH6 in human
glioblastomas is associated with tumor progression during
temozolomide treatment. Clin Cancer Res. 13:2038–2045. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weller M: Where does
O6-methylguanine DNA methyltransferase promoter
methylation assessment place temozolomide in the future standards
of care for glioblastoma? Cancer. 124:1316–1318. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horbinski C, Nabors LB, Portnow J,
Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao
S, et al: NCCN Guidelines® Insights: Central Nervous
System Cancers, Version 2.2022: Featured Updates to the NCCN
Guidelines. J Natl Comp Cancer Network. 21:12–20. 2023. View Article : Google Scholar
|
|
17
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-Year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roldán Urgoiti GB, Singh AD and Easaw JC:
Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. J Neurooncol. 108:173–177. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malkoun N, Chargari C, Forest F, Fotso MJ,
Cartier L, Auberdiac P, Thorin J, Pacaut C, Peoc'h M, Nuti C, et
al: Prolonged temozolomide for treatment of glioblastoma:
Preliminary clinical results and prognostic value of p53
overexpression. J Neurooncol. 106:127–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hau P, Koch D, Hundsberger T, Marg E,
Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, et
al: Safety and feasibility of long-term temozolomide treatment in
patients with high-grade glioma. Neurology. 68:688–690. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Refae AA, Ezzat A, Salem DA and Mahrous M:
Protracted adjuvant temozolomide in glioblastoma multiforme. J
Cancer Ther. 6:748–758. 2015. View Article : Google Scholar
|
|
23
|
Balana C, Vaz MA, Manuel Sepúlveda J,
Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las
Peñas R, Fuster J, et al: A phase II randomized, multicenter,
open-label trial of continuing adjuvant temozolomide beyond 6
cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol.
22:1851–1861. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bady P, Sciuscio D, Diserens AC, Bloch J,
van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L,
Heppner FL, et al: MGMT methylation analysis of glioblastoma on the
Infinium methylation BeadChip identifies two distinct CpG regions
associated with gene silencing and outcome, yielding a prediction
model for comparisons across datasets, tumor grades, and
CIMP-status. Acta Neuropathol. 124:547–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vlassenbroeck I, Califice S, Diserens AC,
Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard
I, Delorenzi M, et al: Validation of real-time methylation-specific
PCR to determine O6-methylguanine-DNA methyltransferase gene
promoter methylation in glioma. J Mol Diagn. 10:332–337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Capper D, Weissert S, Balss J, Habel A,
Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H,
et al: Characterization of R132H mutation-specific IDH1 antibody
binding in brain tumors. Brain Pathol. 20:245–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Franceschi E, Lombardi G, Balestrini D,
Buglione M, Caranci F, Castellano A, Ferreri A, Franchino F,
Giangaspero F and Mascarin M: Guidelines for brain neoplasies|AIOM.
https://www.aiom.it/linee-guida-aiom-2021-neoplasie-cerebrali/June
23–2023
|
|
29
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weller M, van den Bent M, Preusser M, Le
Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven
L, et al: EANO guidelines on the diagnosis and treatment of diffuse
gliomas of adulthood. Nat Rev Clin Oncol. 18:170–186. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Balañá C, Vaz MA, Lopez D, de la Peñas R,
García-Bueno JM, Molina-Garrido MJ, Sepúlveda JM, Cano JM, Bugés C,
Sanz SM, et al: Should we continue temozolomide beyond six cycles
in the adjuvant treatment of glioblastoma without an evidence of
clinical benefit? A cost analysis based on prescribing patterns in
Spain. Clin Transl Oncol. 16:273–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Attarian F, Taghizadeh-Hesary F,
Fanipakdel A, Javadinia SA, Porouhan P, PeyroShabany B and
Fazilat-Panah D: A systematic review and meta-analysis on the
number of adjuvant temozolomide cycles in newly diagnosed
glioblastoma. Front Oncol. 11:7794912021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blumenthal DT, Gorlia T, Gilbert MR, Kim
MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V,
Perry JR, et al: Is more better? The impact of extended adjuvant
temozolomide in newly diagnosed glioblastoma: A secondary analysis
of EORTC and NRG oncology/RTOG. Neuro Oncol. 19:1119–1126. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perry JR, Bélanger K, Mason WP, Fulton D,
Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD,
et al: Phase II trial of continuous dose-intense temozolomide in
recurrent malignant glioma: RESCUE study. J Clin Oncol.
28:2051–2057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van den Bent MJ, Dubbink HJ, Marie Y,
Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe
D, Idbaih A, et al: IDH1 and IDH2 mutations are prognostic but not
predictive for outcome in anaplastic oligodendroglial tumors: A
report of the European organization for research and treatment of
cancer brain tumor group. Clin Cancer Res. 16:1597–1604. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Wang T, Liu W, Qiu H, Zhang N,
Chen X, Ding X and Zhang L: Extended adjuvant temozolomide in newly
diagnosed glioblastoma: A single-center retrospective study. Front
Oncol. 12:10005012022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Darlix A, Baumann C, Lorgis V,
Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech
F, Beauchesne P and Taillandier L: Prolonged administration of
adjuvant temozolomide improves survival in adult patients with
glioblastoma. Anticancer Res. 33:3467–3474. 2013.PubMed/NCBI
|
|
38
|
Bocangel D, Sengupta S, Mitra S and Bhakat
KK: p53-Mediated down-regulation of the human DNA repair gene
O6-methylguanine-DNA methyltransferase (MGMT) via interaction with
Sp1 transcription factor. Anticancer Res. 29:3741–3750.
2009.PubMed/NCBI
|
|
39
|
Weller M, Felsberg J, Hartmann C, Berger
H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn
JC, et al: Molecular predictors of progression-free and overall
survival in patients with newly diagnosed glioblastoma: a
prospective translational study of the German glioma network. J
Clin Oncol. 27:5743–5750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pollack IF, Finkelstein SD, Burnham J,
Holmes EJ, Hamilton RL, Yates AJ, Finlay JL and Sposto R;
Children's Cancer Group, : Age and TP53 mutation frequency in
childhood malignant gliomas: Results in a multi-institutional
cohort. Cancer Res. 61:7404–7407. 2001.PubMed/NCBI
|
|
41
|
Miyagami M, Tazoe M and Nakamura S:
Expression of vascular endothelial growth factor and p53 protein in
association with neovascularization in human malignant gliomas.
Brain Tumor Pathol. 15:95–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Skardelly M, Dangel E, Gohde J, Noell S,
Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S,
et al: Prolonged temozolomide maintenance therapy in newly
diagnosed glioblastoma. Oncologist. 22:570–575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seiz M, Krafft U, Freyschlag CF, Weiss C,
Schmieder K, Lohr F, Wenz F, Thomé C and Tuettenberg J: Long-term
adjuvant administration of temozolomide in patients with
glioblastoma multiforme: Experience of a single institution. J
Cancer Res Clin Oncol. 136:1691–1695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hammouch F, Boterberg T, Clement P,
Joosens E, Whenham N, Verschaeve V, Devriendt D, Renard L and
Baurain JFR: 8744 POSTER extended use of adjuvant TMZ in newly
diagnosed GBM patients is safe-results from the safety analysis of
the PATSGO trial. Eur J Cancer. 47 (Suppl 1):S5872011. View Article : Google Scholar
|
|
45
|
Pouratian N, Gasco J, Sherman JH, Shaffrey
ME and Schiff D: Toxicity and efficacy of protracted low dose
temozolomide for the treatment of low grade gliomas. J Neurooncol.
82:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su YB, Sohn S, Krown SE, Livingston PO,
Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA and Chapman
PB: Selective CD4+ lymphopenia in melanoma patients treated with
temozolomide: A toxicity with therapeutic implications. J Clin
Oncol. 22:610–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Momota H, Narita Y, Miyakita Y and Shibui
S: Secondary hematological malignancies associated with
temozolomide in patients with glioma. Neuro Oncol. 15:14452013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ohno M, Miyakita Y, Takahashi M,
Yanagisawa S, Tamura Y and Narita Y: Continuing maintenance
temozolomide therapy beyond 12 cycles confers no clinical benefit
over discontinuation at 12 cycles in patients with IDH1/2-wildtype
glioblastoma. Jpn J Clin Oncol. 52:1134–1142. 2022.PubMed/NCBI
|
|
49
|
Johnson BE, Mazor T, Hong C, Barnes M,
Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et
al: Mutational analysis reveals the origin and therapy-driven
evolution of recurrent glioma. Science. 343:189–193. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schlesner M and Eils R: Hypermutation
takes the driver's seat. Genome Med. 7:312015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stritzelberger J, Distel L, Buslei R,
Fietkau R and Putz F: Acquired temozolomide resistance in human
glioblastoma cell line U251 is caused by mismatch repair deficiency
and can be overcome by lomustine. Clin Transl Oncol. 20:508–516.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lombardi G, Barresi V, Indraccolo S,
Simbolo M, Fassan M, Mandruzzato S, Simonelli M, Caccese M, Pizzi
M, Fassina A, et al: Pembrolizumab activity in recurrent high-grade
gliomas with partial or complete loss of mismatch repair protein
expression: A monocentric, observational and prospective pilot
study. Cancers (Basel). 12:22832020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bhandari M, Gandhi AK, Devnani B, Kumar P,
Sharma DN and Julka PK: Comparative study of adjuvant temozolomide
six cycles versus extended 12 cycles in newly diagnosed
glioblastoma multiforme. J Clin Diagn Res. 11:XC04–XC08.
2017.PubMed/NCBI
|
